Preventing Tolerance to Oxymetazoline in Allergic Rhinitis

Launched by BRIAN J LIPWORTH · Feb 17, 2009

Keywords

ClinConnect Summary

Allergic rhinitis (AR) affects upto 25% of the worldwide population and is associated with asthma, with Scotland having the highest prevalence in the world. Nasal blockage is the main symptom of allergic rhinitis. Nasal blockage affects sleep quality and impairs daytime performance. It is a major cause of sickness absenteeism and has been shown to adversely affect quality of life. The most efficacious class of drugs for nasal blockage in AR are the nasal decongestants (sympathomimetics acting on alpha receptors which unblock the nose). These are available over the counter for routine use by...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Male of Female aged 18-65 years.
• • Persistent allergic rhinitis with or without asthma.
• • Atopy to atleast one allergen on SPT.
• • PNIF \< 120 L/min (best of 3) and reversibility with OXY \>20L/min.
• • Ability to give a written informed consent.
• • Ability and willingness to comply with the requirements of the protocol.
• Exclusion Criteria:
• • Recent respiratory tract/sinus infection within the last 2 months. .
• • Pregnancy, planned pregnancy or lactation.
• • Known or suspected hypersensitivity to any of the IMP's.
• • Concomitant use of medicines (prescribed, OTC or herbal) like alpha blockers that may interfere with the trial.
• • Nasal Polyposis grade 2+, Deviated nasal septum ≥ 50%
• • The use of oral corticosteroids within the last 3 months.